Nuzenio

Altimmune Initiates Performa

Altimmune Initiates Performa news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 5 publisher sources 100/100 entity strength

Latest news

Altimmune to discuss its liver-treatment candidate Aug. 12 - Stock TitanStock Titan · Wed, 05 Aug 2026 12:00:00 GMTAltimmune (ALT) CSO acquires 875 ESPP shares at $2.414 - Stock TitanStock Titan · Mon, 03 Aug 2026 20:06:31 GMTAltimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan - Stock TitanStock Titan · Mon, 03 Aug 2026 20:06:19 GMTAltimmune initiates PERFORMA trial - TipRanksTipRanks · Mon, 03 Aug 2026 15:16:21 GMTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 12:00:00 GMTAltimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial - TradingViewTradingView · Tue, 28 Jul 2026 14:04:17 GMTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - The Manila TimesThe Manila Times · Tue, 28 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 12:00:00 GMTAltimmune to discuss its liver-treatment candidate Aug. 12 - Stock Titan
Mon, 03 Aug 2026 20:06:31 GMTAltimmune (ALT) CSO acquires 875 ESPP shares at $2.414 - Stock Titan
Mon, 03 Aug 2026 20:06:19 GMTAltimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan - Stock Titan
Mon, 03 Aug 2026 15:16:21 GMTAltimmune initiates PERFORMA trial - TipRanks
Mon, 03 Aug 2026 12:00:00 GMTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - Yahoo Finance
Tue, 28 Jul 2026 14:04:17 GMTAltimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Altimmune Initiates Performa.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.